201 related articles for article (PubMed ID: 37526372)
41. L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia.
Rathi B; Azad RK; Vasudha N; Hissaria P; Sawlani V; Gupta RK
Pediatr Neurosurg; 2002 Oct; 37(4):203-5. PubMed ID: 12372914
[TBL] [Abstract][Full Text] [Related]
42. A Case of ALL Developing Posterior Reversible Encephalopathy Secondary to Hyponatremia.
Eroglu N; Bahadir A; Erduran E
J Pediatr Hematol Oncol; 2017 Nov; 39(8):e476-e478. PubMed ID: 28338570
[TBL] [Abstract][Full Text] [Related]
43. High incidence of hypertension in children presenting with acute lymphoblastic leukemia.
Attard-Montalto SP; Saha V; Ng YY; Kingston JE; Eden OB
Pediatr Hematol Oncol; 1994; 11(5):519-25. PubMed ID: 7826847
[TBL] [Abstract][Full Text] [Related]
44. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
45. Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Retrospective Cohort Study.
Dujua AC; Hernandez FG
J Pediatr Hematol Oncol; 2017 Apr; 39(3):e116-e123. PubMed ID: 28085747
[TBL] [Abstract][Full Text] [Related]
46. Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia.
Eguiguren JM; Pui CH
Med Pediatr Oncol; 1992; 20(1):58-60. PubMed ID: 1727213
[TBL] [Abstract][Full Text] [Related]
47. Reversible acute methotrexate leukoencephalopathy: atypical brain MR imaging features.
Ziereisen F; Dan B; Azzi N; Ferster A; Damry N; Christophe C
Pediatr Radiol; 2006 Mar; 36(3):205-12. PubMed ID: 16369780
[TBL] [Abstract][Full Text] [Related]
48. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
49. [Clinical characteristics and prognosis of seizures in 75 children with acute lymphoblastic leukemia].
Liu J; Lu AD; Zuo YX; Wu J; Huang ZZ; Jia YP; Ding MM; Zhang LP; Qin J
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):948-953. PubMed ID: 36241238
[TBL] [Abstract][Full Text] [Related]
50. Posterior reversible encephalopathy syndrome in pediatric patients: pathophysiology, diagnosis, and management.
Ghali MGZ; Davanzo J; Leo M; Rizk E
Leuk Lymphoma; 2019 Oct; 60(10):2365-2372. PubMed ID: 31556774
[TBL] [Abstract][Full Text] [Related]
51. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
52. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J;
J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397
[TBL] [Abstract][Full Text] [Related]
53. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
[TBL] [Abstract][Full Text] [Related]
54. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
[TBL] [Abstract][Full Text] [Related]
55. The utility of performing the initial lumbar puncture on day 8 in remission induction therapy for childhood acute lymphoblastic leukemia: TCCSG L99-15 study.
Hasegawa D; Manabe A; Ohara A; Kikuchi A; Koh K; Kiyokawa N; Fukushima T; Ishida Y; Saito T; Hanada R; Tsuchida M;
Pediatr Blood Cancer; 2012 Jan; 58(1):23-30. PubMed ID: 21254378
[TBL] [Abstract][Full Text] [Related]
56. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.
Amylon MD; Shuster J; Pullen J; Berard C; Link MP; Wharam M; Katz J; Yu A; Laver J; Ravindranath Y; Kurtzberg J; Desai S; Camitta B; Murphy SB
Leukemia; 1999 Mar; 13(3):335-42. PubMed ID: 10086723
[TBL] [Abstract][Full Text] [Related]
57. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment.
Nowak-Göttl U; Kenet G; Mitchell LG
Best Pract Res Clin Haematol; 2009 Mar; 22(1):103-14. PubMed ID: 19285277
[TBL] [Abstract][Full Text] [Related]
58. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
Dopfer R; Henze G; Bender-Götze C; Ebell W; Ehninger G; Friedrich W; Gadner H; Klingebiel T; Peters C; Riehm H
Blood; 1991 Nov; 78(10):2780-4. PubMed ID: 1824271
[TBL] [Abstract][Full Text] [Related]
59. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
[TBL] [Abstract][Full Text] [Related]
60. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
